miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discovering and developing innovative microRNA-targeting therapies to improve human health. At miRagen Therapeutics we leverage in-house expertise in microRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class microRNA-based technologies and high-potential drug candidates.

We have developed ongoing, collaborative relationships with academic institutions that give us unique access to promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of microRNA-targeting therapeutics.

Our microRNA development platform serves as the foundation for a diversified pipeline. Our therapeutic areas of focus include cancer, pathologic fibrosis, and cardiovascular diseases.